These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 12699745)
1. Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity. Sznaidman ML; Haffner CD; Maloney PR; Fivush A; Chao E; Goreham D; Sierra ML; LeGrumelec C; Xu HE; Montana VG; Lambert MH; Willson TM; Oliver WR; Sternbach DD Bioorg Med Chem Lett; 2003 May; 13(9):1517-21. PubMed ID: 12699745 [TBL] [Abstract][Full Text] [Related]
2. A short and efficient synthesis of the pharmacological research tool GW501516 for the peroxisome proliferator-activated receptor delta. Wei ZL; Kozikowski AP J Org Chem; 2003 Nov; 68(23):9116-8. PubMed ID: 14604391 [TBL] [Abstract][Full Text] [Related]
3. Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Stephen RL; Gustafsson MC; Jarvis M; Tatoud R; Marshall BR; Knight D; Ehrenborg E; Harris AL; Wolf CR; Palmer CN Cancer Res; 2004 May; 64(9):3162-70. PubMed ID: 15126355 [TBL] [Abstract][Full Text] [Related]
4. Parallel Chemistry Approach to Identify Novel Nuclear Receptor Ligands Based on the GW0742 Scaffold. Teske KA; Rai G; Nandhikonda P; Sidhu PS; Feleke B; Simeonov A; Yasgar A; Jadhav A; Maloney DJ; Arnold LA ACS Comb Sci; 2017 Oct; 19(10):646-656. PubMed ID: 28825467 [TBL] [Abstract][Full Text] [Related]
5. Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Tanaka T; Yamamoto J; Iwasaki S; Asaba H; Hamura H; Ikeda Y; Watanabe M; Magoori K; Ioka RX; Tachibana K; Watanabe Y; Uchiyama Y; Sumi K; Iguchi H; Ito S; Doi T; Hamakubo T; Naito M; Auwerx J; Yanagisawa M; Kodama T; Sakai J Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15924-9. PubMed ID: 14676330 [TBL] [Abstract][Full Text] [Related]
6. Structural requirements and cell-type specificity for ligand activation of peroxisome proliferator-activated receptors. Johnson TE; Holloway MK; Vogel R; Rutledge SJ; Perkins JJ; Rodan GA; Schmidt A J Steroid Biochem Mol Biol; 1997; 63(1-3):1-8. PubMed ID: 9449199 [TBL] [Abstract][Full Text] [Related]
7. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Oliver WR; Shenk JL; Snaith MR; Russell CS; Plunket KD; Bodkin NL; Lewis MC; Winegar DA; Sznaidman ML; Lambert MH; Xu HE; Sternbach DD; Kliewer SA; Hansen BC; Willson TM Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5306-11. PubMed ID: 11309497 [TBL] [Abstract][Full Text] [Related]
8. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. Willson TM; Cobb JE; Cowan DJ; Wiethe RW; Correa ID; Prakash SR; Beck KD; Moore LB; Kliewer SA; Lehmann JM J Med Chem; 1996 Feb; 39(3):665-8. PubMed ID: 8576907 [No Abstract] [Full Text] [Related]
10. A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential. Dey D; Medicherla S; Neogi P; Gowri M; Cheng J; Gross C; Sharma SD; Reaven GM; Nag B Metabolism; 2003 Aug; 52(8):1012-8. PubMed ID: 12898466 [TBL] [Abstract][Full Text] [Related]
11. Evidence for peroxisome proliferator-activated receptor (PPAR)alpha-independent peroxisome proliferation: effects of PPARgamma/delta-specific agonists in PPARalpha-null mice. DeLuca JG; Doebber TW; Kelly LJ; Kemp RK; Molon-Noblot S; Sahoo SP; Ventre J; Wu MS; Peters JM; Gonzalez FJ; Moller DE Mol Pharmacol; 2000 Sep; 58(3):470-6. PubMed ID: 10953038 [TBL] [Abstract][Full Text] [Related]
12. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. Berger J; Leibowitz MD; Doebber TW; Elbrecht A; Zhang B; Zhou G; Biswas C; Cullinan CA; Hayes NS; Li Y; Tanen M; Ventre J; Wu MS; Berger GD; Mosley R; Marquis R; Santini C; Sahoo SP; Tolman RL; Smith RG; Moller DE J Biol Chem; 1999 Mar; 274(10):6718-25. PubMed ID: 10037770 [TBL] [Abstract][Full Text] [Related]
13. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Dressel U; Allen TL; Pippal JB; Rohde PR; Lau P; Muscat GE Mol Endocrinol; 2003 Dec; 17(12):2477-93. PubMed ID: 14525954 [TBL] [Abstract][Full Text] [Related]
15. Novel VDR antagonists based on the GW0742 scaffold. Teske KA; Bogart JW; Arnold LA Bioorg Med Chem Lett; 2018 Feb; 28(3):351-354. PubMed ID: 29287957 [TBL] [Abstract][Full Text] [Related]
16. Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor delta. Krämer DK; Al-Khalili L; Perrini S; Skogsberg J; Wretenberg P; Kannisto K; Wallberg-Henriksson H; Ehrenborg E; Zierath JR; Krook A Diabetes; 2005 Apr; 54(4):1157-63. PubMed ID: 15793256 [TBL] [Abstract][Full Text] [Related]